Gordon Hamilton, n/a

Depixus, Ile-de-France, France

Gordon Hamilton is a founder and the CEO of Depixus, a Paris-based biotechnology company pioneering a powerful new technology for studying biomolecular interactions. He has led the company from its inception through to the present day. He previously worked as a Medical Director for ChemoCentryx, a US biopharmaceutical company developing drug targeting the chemokine system (recently acquired by Amgen), where he helped to advance several drugs through Phases I & II of clinical development. Prior to that he worked as a physician in the UK. He holds medical degrees from Oxford University and Imperial College and an MBA from INSEAD.

Disclosure information not submitted.

Presentation(s):

• Introducing MAGNA - single-molecule magnetic force spectroscopy to provide new views into the dynamics of biomolecular interactions

  Tuesday, February 6, 2024
  12:00 PM – 12:20 PM EST

• Revealing the detail: use of single-molecule magnetic force spectroscopy to provide new views into the dynamics of biomolecular interactions.

  Wednesday, February 7, 2024
  10:00 AM – 10:30 AM EST